Adocia has regained global rights to M1Pram after Sanofi's exclusive negotiation period expired.
1 report, 1 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Adocia has regained global rights to M1Pram after Sanofi's exclusive negotiation period expired.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sanofi
French pharmaceutical company
Nothing else this week.